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Abstract 
The goal of this study was to determine the role of the Organic Anion Transporting 
Polypeptides, OATP1A2, OATP1B1 and OATP1B3 and their genetic variants in the 
pharmacokinetics of the immunosuppressive drug mycophenolate mofetil (MMF). Using 
OATP-transfected HEK cells, we measured the uptake of mycophenolic acid (MPA) and its 
glucuronide (MPAG).  MPAG, but not MPA, significantly accumulated in cells expressing 
OATP1B3 or OATP1B1 (p<0.05). MPA and MPAG pharmacokinetics were significantly 
influenced by the OATP1B3 polymorphism, 334T>G/699G>A, in 70 renal transplant patients 
co-treated with tacrolimus or sirolimus but not in 115 patients co-treated with cyclosporine.  
The decrease in MPA dose-normalized exposure and concomitant increase in the 
MPAG/MPA metabolic ratio are consistent with reduced enterohepatic cycling in patients 
carrying the OATP1B3 334G-699A haplotype.  Further studies demonstrated that this variant 
of OATP1B3 exhibited a reduced V
max
 in transfected HEK cells, providing functional support 
of our clinical findings.  
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Introduction 
Mycophenolic acid (MPA), the active moiety of mycophenolate mofetil (MMF), is a non-
nephrotoxic, cornerstone immunosuppressant in kidney transplantation. MPA undergoes 
extensive entero-hepatic recirculation initiated by almost complete hepatic glucuronidation 
into the inactive MPA-7-O-glucuronide (MPAG) (1) and active biliary excretion of this 
metabolite by the Multidrug Resistance-associated Protein-2 (MRP2) (2). It is thought that, 
after MPAG hydrolysis by intestinal flora, the amount of MPA reabsorbed could represent 10 
to 60% of total MPA exposure (1). Consequently, inhibitors of MPA entero-hepatic cycling 
(including cyclosporine) affect MPA levels (3, 4). Although significant associations between 
polymorphisms in enzymes involved in MPA glucuronidation and MMF pharmacokinetics 
were described, results differed depending on the post-transplantation period and 
comedications and could not always be replicated (see supplementary Table 1). The hepatic 
uptake of MPA and/or MPAG being a prerequisite for MPA entero-hepatic recirculation, it 
could contribute to the pharmacokinetic variability and drug-drug interactions of MPA-based 
formulations. There has been only one indirect hint about the implication of the Organic 
Anion Transporting Polypeptides (OATPs) localized to the sinusoidal membrane of the 
hepatocytes in the disposition of MMF. Specifically, Miura et al. reported an association 
between OATP1B3 and OATP1B1 polymorphisms and MPAG and MPA pharmacokinetics in 
Japanese renal transplants (5, 6). 
This study aimed to determine whether MPA and MPAG are substrates of the main OATP 
expressed in hepatocytes (OATP1B1 and 1B3) or enterocytes (OATP1A2) and the effect of 
genetic variations in competent transporters on MPA pharmacokinetics in renal transplant 
recipients receiving MMF combined with different other immunosuppressants, taking into 
account other SNPs previously reported to affect MPA pharmacokinetics. 
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Results 
 
Cellular uptake of MPA and MPAG in OATP-expressing cells 
After 5 min incubation in cells expressing OATP1A2, 1B1 or 1B3, accumulation of MPA was 
not affected as compared to that observed in cells transfected with an empty vector (Figure 
1a). In contrast, MPAG uptake was significantly and substantially enhanced by OATP1B3 
and to a lesser extent by OATP1B1, but not by OATP1A2 (Figure 1b).  
Experiments with radiolabeled model substrates confirmed the activity of each transporter 
(see supplementary data). 
 
Identification and frequency distribution of patient genotypes 
Our clinical pharmacogenetic investigation was primarily based on our aforementioned in-
vitro results and thus aimed to assess the effect of SLCO1B3 and SLCO1B1 polymorphisms 
on MMF pharmacokinetics. In addition, patients were genotyped for polymorphisms in 
UGT1A9, UGT1A8 and ABCC2, previously reported to significantly affect MPA 
pharmacokinetics. 
SNPs to be investigated in SLCO genes were selected from the literature and from the 
SOPHIE (Study of Pharmacogenetics in Ethnically Diverse Populations) database 
(http://pharmacogenetics.ucsf.edu/index.html). Two frequent coding, non-synonymous SNPs 
in complete linkage disequilibrium were reported in SLCO1B3 (T334G, G699A) (7). In the 
Caucasian group of the SOPHIE cohort one additional common non-synonymous SNP was 
found in SLCO1B3 (G767C) with allele frequency of 0.18, and three in SLCO1B1 (A388G, 
C463A and T521C) with allelic frequencies of 0.44, 0.16 and 0.17, respectively.  
No linkage disequilibrium was observed between the SLCO1B3 T334G and G767C SNPs. In 
contrast, for SLCO1B1, the A388G SNP showed a strong linkage disequilibrium with the 
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C463A (D’=1; r
2
=0.21) and the T521C (D’=0.79; r
2
=0.17) SNPs, while there was no linkage 
between the C463A and the T521C SNPs. This lead to six SLCO1B1 haplotypes: A-C-T 
(0.53), G-C-C (known as SLCO1B1*15; 0.15), G-C-T (0.14), G-A-T (0.13), A-C-C (0.021), 
and G-A-C (0.004). 
All genotypes were in Hardy-Weinberg equilibrium. Their distributions were compared to 
those observed in the HapMap Caucasian panel (www.hapmap.org; Release 27, Feb 09), 
except for UGT1A9 C-440T, T98C and SLCO1B3 C767G, not reported in HapMap. No 
significant difference was found, except for ABCC2 C-24T (p=0.01592) whose allelic 
distribution was however not significantly different from that reported in the literature for 
Caucasians (8, 9).  
 
Influence of comedications on MPA pharmacokinetics 
As the nature of the immunosuppressant coadministered with MMF influences MPA 
pharmacokinetics, this effect was evaluated before the pharmacogenetic association study. 
Since no difference in MMF dose (1416±528 vs 1304±478 mg; p=0.3633), MPA dose-
normalized (dn) AUC
0-12h 
(64.6±34.7 vs 66.0±29.7 mg.h/l/g, p=0.6401), dn-C
0
 (4.4±3.5 vs 
3.9±2.5 mg/l/g, p=0.6958) and dn-C
max,
 (20.1±9.4 vs 27.2±21 mg/l/g, p=0.2674) or MPAG 
dn-AUC
0-9h
 (1011±595 vs 1183±611 mg.h/l/g; p=0.1220), dn-C
0
 (99±75 vs 108±59 mg/l/g, 
p=0.3436) and dn-C
max 
(152±84 vs 177±95 mg/l/g, p=0.2059) was observed between patients 
receiving the drug in combination with sirolimus or tacrolimus, the two sub-groups of patients 
were combined for the pharmacogenetic study. In contrast, patients co-treated with 
cyclosporine were studied independently as they received significantly higher doses of MMF 
(1890±679mg) and had lower MPA dn-AUC
0-12h 
(44.3±20.8 mg.h/l/g) as compared to patients 
on sirolimus or tacrolimus (p<0.0001). 
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SLCO genotypes and MMF pharmacokinetics  
In patients receiving MMF in combination with cyclosporine (n=115), no significant 
association between SLCO1B3 or 1B1 genotypes or haplotypes and MPA dn-AUC
0-12h
 was 
found (Table 1). 
In 70 patients co-treated with sirolimus or tacrolimus, MPAG dn-AUC
0-9h
 showed a trend to a 
gradual decrease with the number of SLCO1B3 T334 alleles (Table 2). Although not 
significant, important differences in MPAG dose-normalized levels were observed at all the 
sampling time points (Figure 2b). The metabolic ratio of MPAG to MPA showed a very 
significant decrease in carriers of the SLCO1B3 T334 allele (p=0.0001) (Figure 2c).  
In these patients, MPA dose-normalized exposure was significantly different depending on 
SLCO1B3 T334G genotype (Table 2): the SLCO1B3 T334 allele resulted in significantly 
higher MPA dose-normalized levels at every concentration-time points, except T
20min
 
(p=0.0636) and T
120min
 (p=0.0975) (Figure 2a). Consequently, carriers of a least one 
SLCO1B3 T334 allele (n=22) had 1.42-fold higher (IC95%: 1.39-1.45; p=0.0003) MPA dn-
AUC
0-12h
 and a 1.38-fold higher (IC95%: 1.32-1.49; p=0.0010) dn-C
max
 as compared to 
carriers of the 334GG genotype (n=48). There was no difference in T
max
 (Table 2). MPA 
AUC
4-9h
 was studied as a surrogate for enterohepatic cycling: patients heterozygous or 
homozygous for the SLCO1B3 T334 allele (n=22) had significantly higher MPA dn-AUC
4-9h
 
than other patients (n=48; p=0.0027). However, they also had higher dn-AUC
0-4h 
(p=0.0008), 
resulting in unchanged AUC
4-9h
/AUC
0-9h
 ratio (p=0.4945). 
The SLCO1B3 T334 allele was associated with a similar increase in MPA dn-AUC
0-12h
 
(p=0.0074 and p=0.0651, respectively) and decrease in MPAG/MPA metabolic ratio 
(p=0.0517 and 0.0002, respectively) in the subgroups of patients co-treated with sirolimus 
(n=42) and tacrolimus (n=28). 
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There was no association between the SLCO1B3 T334G genotype and MMF daily dose, 
categorized as low (≤1g), intermediate (=1.5g) or standard/high (≥2g) (p=0.1080). However, a 
significant association was observed between this genotype and MPA AUC
0-12h
 categorized as 
below, in, or above the generally admitted therapeutic range (30-60 mg.h/l; p=0.03548). One 
third of the patients with the 334 TT or TG genotype (n=7/22) had MPA AUC
0-12h
 higher than 
the admitted therapeutic range, as compared to only 8% of patients of the 334GG genotype 
(n=4/48). Conversely, in carriers of the 334GG genotype, 40% (n=19/48) had MPA AUC
0-12h
 
below the therapeutic range as compared to 23% (n=5/22) patients of the TT or TG genotype. 
There was no association of the second SLCO1B3 SNP tested (G767C) with any of the 
exposure indices. 
Despite a trend to higher MPA dn-AUC
0-12h
 in heterozygous carriers of the SLCO1B1 T521C 
SNP as compared to homozygous TT521 carriers (p=0.0534), this SNP was not associated 
with MPAG exposure (Table 2). The other SLCO1B1 SNP tested (A388G and C463A) did 
not show any association with MPA or MPAG pharmacokinetics (Table 2).  
Thesias® haplotype analysis revealed an association between the SLCO1B1*15 allele and 
MPA dn-AUC
0-12h 
(p=0.0246) or MPAG/MPA ratio (p=0.0267), but not with MPAG dn-
AUC
0-9h
.  
No statistical interaction between the effect of SLCO1B3 T334G genotype and SLCO1B1*15 
allele was found using ANOVA, but the effect of the SLCO1B1*15 allele did not remain 
significant regarding MPA dn-AUC
0-12h
 (p=0.0553) and only showed a trend regarding 
MPAG/MPA ratio (p=0.0302, NS after Bonferroni correction). In contrast, the effect of 
SLCO1B3 T334G genotype remained highly significant (p values of 0.0008 and 0.0043 for 
MPA dn-AUC
0-12h
 and MPAG/MPA ratio, respectively).  
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UGT and ABCC2 genotypes and MMF pharmacokinetics  
In patients co-treated with cyclosporine, no influence of UGT1A8 and 1A9 polymorphisms 
was observed on MPA dn-AUC
0-12h
 (Table 1). There was a trend towards an association 
between the ABCC2 C-24T SNP and MPA dn-AUC
0-12h
, however, without apparent 
additivity: heterozygotes for this SNP showed higher MPA dn-AUC
0-12h
 than homozygotes 
for the reference or the variant genotype. 
No significant association of ABCC2, UGT1A8 or UGT1A9 genotypes with MPAG exposure 
was found in patients co-treated with tacrolimus or sirolimus (Table 3). Regarding MPA 
pharmacokinetics, a trend to lower MPA dn-C
max
 was found in two patients heterozygous for 
the UGT1A9 T98C genotype as compared to patients of the reference genotype (p=0.0344; 
NS after Bonferroni correction). However, no association between this polymorphism and 
other MPA (or MPAG) exposure indices or with MPAG/MPA ratio was found (Table 3). 
The UGT1A8 C518G SNP tended to be associated with MPA dn-C
0
 (p=0.0130), C
max
 
(p=0.0368) and dn-AUC
0-12h
 (p=0.0171; Table 3) but not with MPAG exposure indices (Table 
3) or MPAG/MPA ratio. Finally, patients homozygous for the UGT1A9 C-440T variant 
genotype (n=4) had significantly lower MPA T
max
 than patients heterozygous or homozygous 
for the reference allele, but similar MPA or MPAG exposure indices. 
 
Transport activity of OATP1B3 reference and variant proteins 
The effect of the SLCO1B3 variant found to be associated with MPA clinical 
pharmacokinetics was investigated in-vitro. 
The uptake of MPAG into cells expressing the OATP1B3 variant protein (i.e., 334G-699A 
haplotype) was markedly lower than in cells expressing the reference sequence. OATP1B3 
variant protein showed a similar K
m
 (122±109 vs 114±69.8 µM) with the reference OATP1B3 
but a reduced V
max
 (313±188 vs 508±205 pmol/min/mg protein, respectively) (Figure 3). 
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Discussion 
This study provides direct evidence that MPAG is a substrate of the liver-specific uptake 
transporter OATP1B3 and that the pharmacokinetics of MPA is significantly influenced by 
the common SLCO1B3 T334G polymorphism of this gene in renal transplant patients 
receiving MMF in a cyclosporine-free immunosuppressive regimen. Reduced transport of 
MPAG was observed in cells expressing this particular OATP1B3 variant, which is consistent 
with the trend towards a gene-dose decrease in MPAG exposure with the number of variant 
alleles observed in these patients. We found a significant decrease in MPA dn-C
max
 and dn-
AUC
0-12h
 in carriers of the 334G allele. Based on our in-vitro findings and on the change in 
MPAG exposure in transplant patients, we suggest that this is secondary to reduced MPAG 
hepatic uptake, hence reduced re-absorption of MPA via the entero-hepatic cycling.  
Entero-hepatic cycling is indeed a major feature of MPA pharmacokinetics and its 
contribution to MPA exposure is well-known. MPAG is extensively produced in the liver, 
partly excreted into the bile and substantially hydrolysed to MPA in the small intestine, 
leading to MPA re-absorption estimated to contribute 10 to 60% to total MPA exposure (1). It 
is generally thought that MPAG biliary excretion occurs just after its production in the liver. 
Here we suggest that, additionally, the active transport of circulating MPAG into hepatocytes 
substantially contributes to MPA enterohepatic cycling and then in MPA systemic exposure. 
Indeed, MPAG plasma concentrations are by far higher than those of MPA and this study 
strongly suggests that MPAG is actively taken up by the hepatocyte. The trend towards higher 
MPAG plasma levels in patients carrying the SLCO1B3 G-allele is consistent with our in-
vitro findings and supports the hypothesis that reduced OATP1B3 activity would decrease 
MPAG hepatic uptake. Nonetheless, the change in MPAG levels was not significant, maybe 
because renal elimination is the main disposition pathway for this metabolite. Thus, despite 
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reducing MPA re-circulation, the decrease in MPAG biliary excretion might have a limited 
effect on MPAG overall elimination.  
We did not observe any association between this SNP and MPA exposure in 115 patients co-
treated with cyclosporine, which might be due to the inhibitory effect of cyclosporine on 
MPA biliary excretion. Inhibition of MRP2 by cyclosporine will indeed reduce MPA 
recirculation, whatever the activity of OATP1B3 is. Looking at the means ± SD in the three 
genotype groups (Table 1) as well as to the p value obtained, it seems that the number of 
patients in this comedication subgroup was sufficient to exclude any clinically relevant 
influence of this particular SNP on MPA exposure in patients receiving cyclosporine. In 
contrast, increasing the number of patients cotreated with tacrolimus or sirolimus might have 
allowed us to investigate a potential additive gene-dose effect. 
Human OATP1B3 is mainly expressed in hepatocytes where it mediates, together with 
OATP1B1, the uptake of a number of drugs or endogenous compounds from blood to 
hepatocytes (10). In this study, we showed that cell expression of either transporter resulted in 
the facilitated uptake of the main metabolite of MPA (MPAG). However, OATP1B1 activity 
with respect to MPAG was relatively modest as compared to that of OATP1B3, suggesting 
limited implication of OATP1B1 in MPAG uptake in-vivo as compared to OATP1B3. The 
finding that none of the OATP1B1 polymorphisms or haplotypes tested in this study was 
significantly and markedly associated with MPA or MPAG pharmacokinetics supports this 
hypothesis.  
We did not observe any difference between HEK293T native and OATP-expressing cells 
regarding the uptake of the parent drug (MPA). We cannot totally exclude that MPA is a 
substrate of OATP. Indeed, passive diffusion (or transport via some unknown transporter in 
HEK) apparently plays a much higher role in MPA than MPAG cellular transport, with a net 
uptake rate approximately 3-fold higher for MPA than MPAG in HEK293T native cells 
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(0.021 vs 0.008 pmol/mg/min). This may mask the active transport of the drug (if any) in our 
cellular model.  
OATP1A2 is highly expressed in the intestine, the kidney, in cholangiocytes and at the blood-
brain barrier (10, 11) where it is supposed to play an important role in drug absorption and 
drug-drug interactions (11). We observed no difference between native and OATP1A2-
expressing HEK293T cells regarding MPA or MPAG uptake, suggesting that these 
compounds are not substrates of OATP1A2.  
The first study investigating the functional consequences of SLCO1B3 polymorphisms 
showed in stably transfected MDCKII and HEK293 cells that variant OATP1B3 proteins 
resulting from either of the two coding non-synonymous SNPs T334G (S122A) and G699A 
(M233I) had similar basolateral membrane localization with the reference protein (12). They 
did not find differences in uptake activities between these proteins using several model 
substrates (Estrone-3-sulfate, bromosulfophthalein and 17-β-glucuronosyl estradiol). 
However, the authors did not investigate the consequence of the combined amino acid 
substitutions resulting from these two SNPs (in complete linkage disequilibrium). Hamada et 
al. found that COS-7 cells transfected with the variant SLCO1B3 haplotype (334G-699A) had 
a significantly reduced ability to uptake testosterone as compared to cells transfected with the 
reference SLCO1B3 gene or a sequence containing either the 334G or the 699A SNP (7). In 
the present study, our SLCO1B3 plasmid integrated simultaneously the two SNPs and we 
obtained results in line with those of Hamada et al., with a decreased uptake of MPAG in cells 
transfected with the 334G-699A variant as compared to the reference sequence. Our clinical 
results are compatible with decreased activity of the OATP1B3 variant protein but 
surprisingly different from those recently published for the same drug in Japanese patients. 
Miura el al. described higher dn-AUC
6-12 
(regarded a marker of MPA recirculation) in patients 
carrying the 334GG (or 699AA) genotype as compared to carriers of the 334TT genotype (6). 
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Based on this pharmacokinetic observation, the authors proposed that MPA uptake into 
hepatocytes and excretion into bile might be increased in patients with SLCO1B3 334GG 
genotype. This is in contradiction with previous (12) and the present in-vitro evidence that the 
334G allele reduces OATP1B3 activity. Also, the present results do not support this 
hypothesis as MPA is not a substrate of OATP1B3 in-vitro, and yet we found a lower dose-
normalized MPA exposure in carriers of the 334GG genotype. It should be noted that Miura 
et al. recently reported, in accordance with our hypothesis, that patients homozygous for the 
SLCO1B3 334G-699A allele had significantly higher MPAG dn-AUC
0-12
 than patients 
heterozygous or homozygous for the reference allele (5).  
We observed an important decrease of MPA exposure in patients receiving MMF combined 
with cyclosporine as compared to tacrolimus or sirolimus. This difference is well-known and 
is thought to result from the inhibitory effect of cyclosporine on MPAG biliary excretion. The 
mechanisms presumably involved in this drug-drug interaction and in the pharmacogenetic 
association we observed are very close. It is even tempting to hypothesise that the inhibitory 
effect of cyclosporine might not only concern MRP2 (as generally admitted) but also 
OATP1B3. Indeed, in-vitro studies showed that cyclosporine is a potent inhibitor of 
OATP1B1 and OATP1B3 (13). This inhibitory effect was associated with drug-drug 
interactions of clinical relevance, in particular with statins (14, 15).  
Most of the pharmacogenetic studies performed regarding MMF focused on UGT enzymes or 
MRP2 but weak associations were mainly reported (see supplementary Table 1). In the 
present study, we tested the effect of SNPs previously associated with MPA pharmacokinetics 
using stringent criteria for statistical analysis (i.e., Bonferroni correction): none of the SNPs 
evaluated significantly influenced MPA pharmacokinetics, whatever the comedication. It is 
possible that this absence of effect, in particular for UGT1A9 SNPs previously associated in-
vitro with a decreased enzyme activity or expression (16, 17) is related to differences in the 
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post-transplantation periods at which patients were studied. Association between the UGT1A9 
C-2152T, T98C or UGT1A8 C518G SNPs were indeed observed in patients studied at early 
post-transplantation periods (<30 days) (18-20), when MPA apparent clearance (CL/F) is 
known to be higher than at later time-points (21), presumably owing to several time-
dependent factors such as the renal function, albumin and haemoglobin levels, decreasing 
cyclosporine predose levels (22) and inductive effect of corticosteroids on UGT (23).  
However, this cannot explain the discrepancy with the significant influence of UGT1A9 C-
440T/T-331C on MPA dn-AUC
0-12h
 found by Baldelli et al. in stable renal transplants 
receiving a steroid-free regimen (9). 
Our study certainly has some limitations: in addition to those mentioned above, potential 
covariates such as serum albumin, previously associated with MPAG disposition in renal 
transplants (9), could not be taken in account in multivariate analyses to ponder the 
associations (or the absence of associations) found here, contrary to what van Shaik et al. 
recently did (20), because they were not available in our databases.  
Apart from the association of SLCO1B3 genotype with MPA pharmacokinetics (of which the 
relevance for MMF efficacy or tolerance remains to be investigated in a larger population), 
our study demonstrates for the first time that OATP proteins are involved in the 
pharmacokinetics of MPA. It gives new hints regarding the mechanism of drug-drug 
interactions, in particular with cyclosporine whose known effects on MPA and MPAG plasma 
levels are similar to those of the mutant SLCO1B3 allele herein.  
In conclusion, the pharmacokinetics of MPA in stable renal transplant patients receiving a 
cyclosporine-free regimen is influenced by genetic polymorphisms of the hepatic uptake 
transporter OATP1B3, of which MPAG is a substrate. Cyclosporine might inhibit the 
transporter function and thus attenuate the effect of its polymorphism.  
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Methods 
Cellular assays 
SLCO1B3-pcDNA5/FRT plasmids containing the reference sequence (NM_019844) or a 
sequence with two nucleotide exchanges corresponding to the SLCO1B3 T334G (rs4149117) 
and SLCO1B3 G699A (rs7311358) polymorphisms were constructed as described in 
supplementary data. SLCO1A2-PSG5 and SLCO1B1-PCMV6-XL4 plasmids were a generous 
gift from Theo J. Visser, Department of Internal Medicine, Erasmus University Medical 
Center. 
Human embryonic kidney (HEK) 293T/17 cell lines (American Type Culture Collection, 
ATCC) were routinely cultured at 37°C with 5% CO
2
 and 95% humidity in low-glucose 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum, 100U/ml 
penicillin, and 100µg/ml streptomycin. Cells were seeded in 10-cm dishes and transfected 
with 10µg of SLCOs cDNA (or empty vector), 20µl of lipofectamine LTX (Invitrogen, 
Carlsbad, CA) and 2ml of Optimem (Invitrogen). 24h after transfection, cells were trypsinized 
and seeded in 24-well poly-d-lysine-coated plates (BD Discovery Labware, Bedford, MA) at 
a density of 1.5x10
5
 cells/well in order to reach confluence within 24h for uptake assays. 
 
Transport activities were analyzed through measuring intra-cellular accumulation of MPA and 
MPAG. (20µM). Uptake was initiated by adding the compounds in Hank’s Buffer Salt 
Solution (HBSS, Invitrogen) after cells had been washed twice and preincubated with HBSS 
at 37°C for 15 min. After 5 to 10 minutes, the cells were washed twice with ice-cold uptake 
buffer, lysed in 250µl of NaCl 0.2N (1 hour at 4°C) and lysates neutralized by adding 25µl of 
2N HCl. MPA and MPAG were determined using a previously described validated liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) assay (3). Results were normalized 
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to per-well protein content as measured using the bicinchoninic acid protein assay (Pierce, 
Rockford, IL).  
OATP1B3-mediated net uptake kinetics was studied after 10 min of incubation with MPAG, 
after subtracting the uptake in empty vector-transfected cells. K
m
 and V
max
 were obtained by 
fitting the Michaelis–Menten equation (GraphPad Software, San Diego, CA).  
 
Clinical pharmacogenetic analysis  
A first group of 70 kidney transplant patients enrolled in one of three phase 4 clinical trials 
gave their informed consent for providing blood samples for pharmacogenetic investigations 
related to the pharmacokinetics of MMF. 42 patients received MMF in combination with 
sirolimus and 28 with tacrolimus. MMF was administered at an initial fixed dose of 1g twice 
daily, which was reduced if necessary based on clinical criteria. Tacrolimus was administered 
twice daily and sirolimus once daily, targeting a whole blood trough concentration between 
0.05 to 0.015 mg/l and 0.010 to 0.012 mg/l, respectively. For MMF pharmacokinetics, blood 
samples were collected in each patient between 3 and 6 months post-grafting at 0, 20, 40, 60, 
90, 120, 180, 240, 360 and 540 min after the morning dose. MPA and MPAG plasma 
concentrations were determined by use of a validated LC-MS/MS method (24). Area under 
the concentration-time curve (AUC
0-12h
) were calculated using validated Bayesian models. In 
the absence of an adequate model for MPAG, AUC
0-9h 
were estimated using the linear 
trapezoidal rule. The plasma metabolic ratio of MPAG to MPA was estimated as the AUC
0-9h
 
ratio. There was no difference in renal function between patients receiving tacrolimus or 
sirolimus as assessed by comparing serum creatinine levels at the time of blood sampling 
(p=0.7659). 
A second group of 115 kidney transplants out of 137 patients enrolled in the multicenter, 
open-label, randomized trial Apomygre (Clinical Trial Registry No. NCT0019967) provided 
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written informed consent for pharmacogenetic investigations related to MMF 
pharmacokinetics. These patients received the drug in combination with cyclosporine. Study 
aim and design, patients population and primary results were recently published (25). Blood 
samples were collected at the same times as in the first group at 3 or 6 months post-
transplantation. MPA AUC
0-12h
 were estimated using concentration at three sampling time 
(20, 60 and 180min) using previously published, validated Bayesian models (21, 26). 
All these trials were approved by ethic committees. 
There was no statistical difference in corticosteroid dose between patients co-treated with 
cyclosporine and tacrolimus or sirolimus at the time of blood sampling (p>0.05). 
Patients’ DNA was isolated from EDTA-treated blood as previously described in details (27) 
and was characterized for SNPs in SLCO1B3, SLCO1B1, UGT1A8, UGT1A9 and ABCC2 
genes using validated TaqMan allelic discrimination assays on an ABI PRISM 7000 Sequence 
Detection System (Applied Biosystems, Courtaboeuf, France).  
Statistical analysis 
Pairwise linkage disequilibrium between polymorphisms was evaluated by means of D’ and r² 
(calculated using Thesias® software (28)) and patients’ most probable haplotypes inferred 
using the PHASE program (29). Categorical variables were compared using the Fisher’s exact 
test and continuous variables using the Kruskal–Wallis or Mann-Whitney tests, or ANOVA 
when studying the interaction between variables. A Bonferroni correction was applied leading 
to a p threshold for significance of 0.005 (analysis of 10 SNPs).All statistical comparisons 
were performed using the StatView program (SAS Institute, Cary, NC, version 5.0).  
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Table 1: Mycophenolic acid (MPA) dose-normalized (dn) AUC
0-12h
 according to 
SLCO, UGT or ABCC2 Single Nucleotide Polymorphisms (SNPs) in patients co-
treated with cyclosporine 
Gene SNP Patients genotypes (n) MPA dn-AUC
0-12h 
(mg.h/l)/g P values 
TT (n=6) 
42.7±18.4 
TG (n=32) 
48.6±22.9 
T334G  
GG (n=76) 
42.7±20.2 
0.4747 
GG (n= 79) 
47.1±23.2 
SLCO1B3 
G767C 
GC (n= 36) 
38.1±12.4 
0.0469 
TT (n=75) 
44.8±20.7 
TC (n=36) 
43.7±22.1 
T521C 
CC (n=4) 
38.6±10.9 
0.7507 
AA (n=37) 
45.5±17.1 
AG (n=52) 
44.1±22.2 
A388G 
GG (n=26) 
42.8±23.3 
0.2800 
CC (n=83) 
43.6±18.3 
CA (n=30) 
46.3±27.0 
SLCO1B1 
C463A 
AA (n=2) 
42.8±25.0 
0.9717 
CC (n=59) 
43.7±18.9 
CG (n=50) 
44.1±22.1 
UGT1A8 C518G 
GG (n=6) 
51.4±29.3 
0.9066 
CC (n=69) 
40.8±15.3 
CT (n=39) 
49.2±27.1 
C-440T 
TT (n=7) 
50.7±24.0 
0.2721 
TT and CC (n=101) 
44.1±21.2 
TA and CT or CC (n=12) 
47.8±19.1 
T-275A and/or C-2152T*  
AA and TT (n=2) 
31.8±7.9 
0.4498 
TT (n=105) 
43.7±21.1 
UGT1A9 
T98C 
TC (n=10) 
50.7±17.1 
0.0634 
CC (n=68) 
40.2±14.5 
CT (n=35) 
53.6±26.0 
ABCC2 C-24T 
TT (n=12) 
39.9±26.7 
0.0087 
*SNPs in strong linkage disequilibrium: D’=1 ; r
2
=0.87  
Table 2: Pharmacokinetic parameters of mycophenolic acid (MPA) and its glucuronide (MPAG) according to SLCO Single Nucleotide 
Polymorphisms (SNPs) in patients co-treated with tacrolimus or sirolimus 
Gene SNP Genotypes (n) MPA  
dn-C
0
  
(mg/l)/g 
MPA 
 dn-C
max 
(mg/l)/g 
MPA  
T
max 
(min) 
MPA  
dn-AUC
0-12h 
(mg.h/l)/g  
MPAG 
 dn-C
0
 (mg/l) 
MPAG  
dn-C
max 
(mg/l) 
MPAG  
T
max 
(min) 
MPAG 
 dn-AUC
0-9h
 
(mg.h/l)  
TT (n= 2) 3.4±0.6 21.4±10.5 65.0±35.3 73.9±30.2 79.6±42.7 111.6±32.8 90.0±42.4 621.7±235.3 
TG (n=20) 5.3±2.8 28.6±10.7 71.5±111.6 82.6±32.6 91.0±51.0 137.4±54.0 114.5±112.1 964.8±457.6 
GG (n=48) 3.7±3.1 20.6±16.7 69.6±86.7 57.5±30.2 108.8±74.7 173.7±98.7 123.3±75.6 1146.2±644.2 
p values 0.0413 
0.0012 
0.8113 
0.0040 
0.6296 0.3664 0.3297 0.2477 
T334G  
p values (TT+TG vs GG) 0.0150 
0.0004 
0.8233 
0.0009 
0.3774 0.1947 0.1364 0.2394 
GG (n=49) 4.4±3.2  23.5±13.2 63.5±74.5 68.5±33.4 103.9±72.1 157.2±82.7 117.9±88.1 1042.6±524.5 
GC (n=21) 3.7±2.7 21.5±19.8 85.2±126.0 57.4±30.0 100.9±60.2 171.7±101.7 124.3±83.5 1165.1±741.9 
SLCO1B3 
G767C 
p values 0.3153 0.1644 0.9183 0.2234 0.9365 0.5010 0.6570 0.4769 
TT (n=47) 3.6±2.3 22.1±17.0 64.0±75.7 60.0±30.0 112.3±76.3 170.0±96.7 116.6±84.1 1137.9±639.8 
TC (n=23) 5.3±4.1 24.6±11.6 82.2±121.0 75.8±35.6 84.8±44.7 144.3±66.6 126.5±91.8 959.7±482.2 
T521C  
p values 0.0942 0.0902 0.6753 0.0534 0.1168 0.2685 0.9695 0.2578 
AA (n=19) 4.0±2.5 18.5±9.0 
80.0±115.2 58.2±30.4 123.9±93.7 167.8±95.9 117.4±114.9 1079.4±545.2 
AG (n=43) 4.0±3.3 23.7±16.3 
71.6±89.9 65.9±33.0 91.0±55.7 156.6±87.1 127.4±75.5 1054.0±634.9 
GG (n=8) 5.2±3.1 29.4±20.5 
37.5±16.7 77.9±34.8 118.9±52.3 173.2±85.5 85.0±58.1 1164.6±542.6 
A388G 
p values 0.4849 0.1966 0.1858 0.2692 0.0883 0.6920 0.2154 0.5720 
CC (n=52) 3.9±2.3 23.3±15.1 74.8±106.4 65.7±33.0 96.7±70.2 154.2±86.1 119.2±90.5 1015.1±562.9 
CA (n=17) 4.6±4.6 22.1±16.9 58.2±21.9 63.5±33.2 119.5±62.6 185.2±96.2 127.6±72.3 1291.0±672.6 
AA (n=1) 8.6 18.3 20.0 62.9 137.0 145.6 20.0 824.9 
SLCO1B1 
C463A 
p values 0.2799 0.7794 0.1598 0.9049 0.1393 0.3723 0.1249 0.1680 
dn: dose-normalized 
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Table 3: Pharmacokinetic parameters of mycophenolic acid (MPA) and its glucuronide (MPAG) according to UGT or ABCC2 Single Nucleotide 
Polymorphisms (SNPs) in patients co-treated with tacrolimus or sirolimus 
Gene SNP Patients 
genotypes (n) 
MPA dn-C
0
 
(mg/l)/g 
MPA dn-C
max 
(mg/l)/g 
MPA T
max 
(min) 
MPA dn-AUC
0-12h 
(mg.h/l)/g  
MPAG dn-C
0
 
(mg/l) 
MPAG dn-
C
max 
(mg/l) 
MPAG T
max 
(min) 
MPAG dn-AUC
0-
9h
 
(mg.h/l) 
CC (n=39) 4.1±3.7 22.0±18.3 75.6±93.8 63.1±35.0 108.5±88.3 171.9±104.2 130.0±95.1 1143.5±692.2 
TC (n=27) 4.1±2.3 23.3±11.3 68.5±97.4 68.7±30.1 95.0±50.6 144.7±59.0 111.5±76.5 974.3±429.7 
TT (n=4) 4.4±2.1 29.0±6.7 25.0±10.0 61.5±17.7 102.2±46.6 174.7±86.4 77.5±35.0 1163.1±559.7 
C-440T  
(T-331C) 
p values 0.5049 0.0753 0.0330 0.5080 0.7807 0.7867 0.3018 0.6777 
TT(CC) (n=63) 4.3±3.1 23.3±15.8 71.9±97.2 65.7±30.4 105.8±69.8 163.4±90.4 118.4±88.9 1090.6±605.2 
TA (CT) (n=7) 2.8±2.8 19.3±11.7 52.8±22.1 60.3±51.2 79.7±50.6 144.9±69.9 132.8±59.6 978.2±523.4 
T-275A or 
C-2152T* 
p values 0.0912 0.3325 0.8469 0.1799 0.5119 0.9143 0.2858 0.9143 
TT (n=68) 4.1±3.0 23.3±15.4 70.1±93.8 66.2±32.5 103.7±68.9 163.4.2±88.7 119.0±87.2 1089.2±599.4 
TC (n=2) 6.1±6.5 8.9±3.1 65.0±35.3 30.9±8.7 78.9±38.3 98.0±51.0 150.0±42.4 745.6±371.3 
UGT1A9 
T98C 
p values 0.5671 0.0344 0.5957 0.0570 0.6764 0.2172 0.2358 0.4175 
CC (n=40) 4.2±3.2 25.4±18.1 69.0±94.5 66.8±29.6 105.1±75.5 166.8±95.4 109.7±73.8 1066.9±587.5 
CG (n=26) 4.5±3.0 21.0±9.8 73.5±97.8 67.9±36.8 105.1±60.9 160.7±41.9 139.6±105.6 1040.4±643.9 
GG (n=4) 1.1±0.4 10.1±6.0 57.5±28.7 30.9±8.3 68.4±30.5 114.2±41.8 92.5±37.7 807.7±263.5 
UGT1A8 C518G 
p values 0.0130 0.0368 0.4694 0.0171 0.5331 0.5350 0.5786 0.6701 
CC (n=48) 4.1±3.2 22.7±17.6 60.4±51.6 64.1±33.0 98.4±72.5 158.1±93.7 127.1±78.0 683.1±299.7 
CT (n=19) 4.7±3.0 23.0±9.8 96.8±157.5 67.4±33.6 112.8±60.1 165.1±75.9 
103.15±110.0
5 
1107.0±648.1 
TT (n=3) 2.6±1.2 26.2±4.7 53.3±11.5 68.0±27.7 116.2±49.4 193.9±95.4 110.0±17.3 1341.8±577.8 
ABCC2 C-24T 
p values 0.5066 0.1804 0.7746 0.8393 0.3411 0.2371 0.0913 0.3835 
*SNPs in complete linkage disequilibrium 
Figure legends 
 
Figure 1: Mycophenolic acid (MPA; a) and mycophenolic acid phenyl-glucuronide (MPAG; 
b) (20µM) uptake into HEK293T cells transiently transfected with OATP1B1, 1B3 and 1A2. 
Empty vector (EV) transfected cells served as control. Data are mean ± SD of three 
independent experiments performed in triplicate. Uptake time was 5 min. (*p<0.05 for 
comparison with control cells). 
 
Figure 2: Mean ± SEM of dose normalized concentration-time profiles of mycophenolic acid 
(MPA; a), MPA-phenyl glucuronide (MPAG; b) and distribution of MPA to MPAG 
metabolic ratio (MPAG/MPA AUC
0-9h
 ratio; c) as a function SLCO1B3 T334G genotype in 
patients co-treated with tacrolimus or sirolimus. In panel c, the lines represent the mean 
values. *p<0.05; **p<0.005 
 
Figure 3: Kinetics of mycophenolic acid phenyl-glucuronide (MPAG) transport by reference 
(T334-G699) and variant (334G-699A OATP1B3. HEK293 cells transiently expressing either 
the OATP-reference or the OATP-variant proteins were incubated in the presence of 
increasing concentrations of MPAG for 10 min. Data were fitted to the Michaelis–Menten 
equation after subtracting background uptake. Data points represent the mean ±SD from n=3 
experiments.  
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